Eledon Pharmaceuticals
↗Irvine, USA
Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for patients requiring organ or cell-based transplants, or living with autoimmune and neurodegenerative diseases. The company's primary focus is the CD40L (CD40 Ligand) pathway, a well-validated biological target that plays a central role in immune cell activation.
Eledon's lead asset, tegoprubart, is a high-affinity anti-CD40L antibody designed to provide a safer, more effective alternative to current standard-of-care immunosuppressants like tacrolimus. The company is actively advancing clinical programs in kidney transplantation, islet cell transplantation for Type 1 Diabetes, and xenotransplantation.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology and Transplantation
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M (Clinical Stage)
Founded:2004
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$192.5M
Investors:Vanguard Group, BlackRock, ALS Investment Fund, Breakthrough T1D (formerly JDRF)
STOCK
Exchange:NASDAQ
Ticker:ELDN
Market Cap:$161M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2 (Advancing to Phase 3)
Modalities:mAb (Monoclonal Antibody)
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Anelixis Therapeutics (Acquired 2020)
Key Partnerships:eGenesis (Xenotransplantation collaboration), University of Chicago Medicine (Islet cell transplantation), Massachusetts General Hospital (Xenotransplantation studies)
COMPETITION
Position:Emerging
Competitors:Sanofi (Frexalimab), Biogen, UCB, Gilead Sciences, Amgen
LEADERSHIP
Key Executives:
David-Alexandre C. Gros - CEO
Steven N. Perrin - President & CSO
Scientific Founders:Dr. Steven Perrin
Board Members:David-Alexandre C. Gros, Steven N. Perrin, June Lee, John S. McBride
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Eledon Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.